Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer. Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer. conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer. Clinical research trials and A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer. healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer.. A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer. Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer. clinical trial. Subjects frequently obtain the most expert healthcare possible for their A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer. condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer.

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer.



A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer.

For Condition: Breast Neoplasms
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.
Details: Gemcitabine is given by vein over 30 minutes on days 1 & 8 of each 21-day cycle. LY231514 is also given by vein over 10 minutes on day 8, following the Gemcitabine injection. Vitamin supplementation with oral folic acid and injectable B12 is initiated 7-10 days prior to the first dose of LY231514, and continuing throughout the patient's participation. Vitamin B12 is administered approximately every 9 weeks after the first injection. Appropriate antiemetic medication should be given to all patients. Dexamethasone 4mg PO twice daily is given for 3 days per cycle, beginning 1 day prior to LY231514 dosing. This is given to prevent or lessen the possibility of a rash.
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - confirmed diagnosis of breast cancer - measurable disease - received prior anthracycline and taxane - life expectancy > 3 months - acceptable lab results Exclusion Criteria: - >3 prior regimens - prior treatment with protocol drugs - prior (pelvic) radiation - active CNS metastasis - inability to take oral vitamins
Total Enrollment: 

Location and Contact Information:


Additional Information:
Study ID Numbers:  2245; 
Study Start Date: 
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034489

Other Breast Neoplasms Studies:
1. Mistletoe Extract and Gemcitabine for the Treatment of Solid Tumor Cancers

2. Safety and efficacy study of the combination of CpG 7909 and Herceptin in patients with metastatic breast cancer

3. A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer

4. Chemotherapy Related Anemia

5. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

Related Studies:

Other Breast Neoplasms Clinical Trials
Other Minnesota Clinical Trials
Other Rochester Clinical Trials

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer.
Modify your Search

  Other Breast Neoplasms Clinical Trials
  Other Minnesota Clinical Trials
  Other Rochester Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103